Please login to the form below

Not currently logged in
Email:
Password:

Ramprasad Reddy to chair Aurobindo’s US business

Will also step down from position as full-time director

P V Ramprasad Reddy, who resigned as executive chair of the board of Indian firm Aurobindo in June, 2012, has been appointed chair of its US subsidiary, Aurobindo Pharma USA.

The decision was approved by Aurobindo's board of directors in a meeting last week, although the proposal is still subject to further approval from shareholders, with an extraordinary general meeting scheduled for September 27, 2012 to confirm the appointment.

If approved, Ramprasad Reddy will assume his new position on December 1, 2012.

In addition, Aurobindo's board also approved that Ramprasad Reddy relinquish his executive responsibilities as full-time director of the company, although he will continue as non-exectuive director.

Ramprasad Reddy also has roles at several other Aurobindo subsidiaries, which include serving as director of APL Pharma Thai Limited, Aurobindo (Datong) Bio-Pharma and Aurobindo Tongling (Datong) Pharmaceutical.

In 2008, World Pharmaceutical Frontiers named Ramprasad Reddy as one of the 35 most influential people in the pharmaceutical industry.

29th August 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health4Brands

At H4B, we are an energetic new team with fresh ideas, but we have over 275 years of combined experience...

Latest intelligence

Leveraging HCP Transparency Insights to Drive Future Customer Investments
EFPIA’s disclosure requirements present an opportunity to assess strategy and effectiveness...
How did pharma use Twitter at #ASCO16?
Each year, ASCO’s Annual Meeting brings together 30,000 oncology professionals from around the world, here we explore the #ASCO16 hashtag and how pharma utilised the channel during this year's event....
WHITE PAPER: How to engage with HCPs more effectively
Shrinking budgets and limitations on the time HCPs can spend with sales reps is making traditional engagement methods more and more ineffective. So, in order to reach the unreachable, pharma...

Infographics